Table 1 Clinical History of Patients with a DDR- related Pancreatic Cancer
From: Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer
| Pt | Sex | Prior cancer | Family historyh |
Dx. age | Clinical stage at dx. | Gene | Variant | Survival (mo.) | Sx. | Chemotherapy | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug | Duration (mo.) | ||||||||||
| 1 | M | – | FDR: Colon (P) | 30–35 | metastatic | BRCA1 | c.34C > T | 25.8 | No | FOLFIRINOX | 5 |
| SDR: Breast (P), Prostate (M), Renal (M) | Erlotinib | 1 | |||||||||
| Gemcitabine, Nab-Paclitaxel | 6 | ||||||||||
| 2 | M | – | FDR: Pancreas (P), Prostate (P), Uterine (M) | 55–60 | metastatic | BRCA1 | c.5080G > T | 23.5 | Yesa | FOLFIRINOX | 3 |
| Gemcitabine, Nab-Paclitaxel | 2 | ||||||||||
| Gemcitabine | 2 | ||||||||||
| Gemcitabine, Cisplatin | 7 | ||||||||||
| 3 | F | breast | FDR: Breast (M), Colon (P) | 40–45 | metastatic | ATM | c.2921 + 1G > A | 13.7 | No | FOLFIRINOX | 8 |
| SDR: Colon (P) | |||||||||||
| 4 | F | bilateral breast | FDR: Breast (M), Colon (P), Ovarian (M) | 50–55 | locally advanced | BRCA1 | c.2722G > T | 111.5 | Yes | Gemcitabine | 6 |
| FOLFIRINOX | 6 | ||||||||||
| SDR: 3 Breast (P) | Gemcitabine, Nab-Paclitaxel | 1 | |||||||||
| Gemcitabine | 8 | ||||||||||
| FOLXFOX | 6 | ||||||||||
| Irinotecan | 3 | ||||||||||
| Nivolumab | 13 | ||||||||||
| Nivolumab, Gemcitabine, Carboplatin | 1 | ||||||||||
| Nivolumab, Gemcitabine | 2 | ||||||||||
| Nivolumab | 1 | ||||||||||
| PARPi (Rucaparib) | 1 | ||||||||||
| 5 | F | – | FDR: Pancreas (M), Prostate (P) | 60–65 | metastatic | ATM | c.7630-2A > C | 20.5 | No | FOLFIRINOX | 14 |
| SDR: Breast (M), 2 Pancreas (M), Prostate (P) | Gemcitabine, Cisplatin | 4 | |||||||||
| 6 | M | – | FDR: Breast (M), Ovarian (M) | 60–65 | locally advanced | BRCA2 | c.9435_9436del | 34.3b | Yesa | FOLFIRINOX | 2 |
| SDR: 2 Breast (P) | Gemcitabine, Capecitabine | 5 | |||||||||
| 7 | M | basal cell carcinoma | SDR: Bladder (M), Breast (P), Colon (P) | 70–75 | locally advanced | FANCC | c.1642C > T | 22.3 | No | Gemcitabine, Nab-Paclitaxel | 4 |
| FOLFIRINOX | 7 | ||||||||||
| 8 | F | – | FDR: Breast (M), Melanoma (M) | 40–45 | localized | PALB2 | c.487_488delGT | 84.4b | Yes | Gemcitabine | 5 |
| SDR: Breast (M) | |||||||||||
| 9 | F | melanoma, bladder | FDR: Breast (M), Melanoma, 2 Pancreatic, Prostate (P) | 80+ | localized | ATM | c.6975 + 2 T > C | 56.6b | Yes | Gemcitabine | 3 |
| 10 | M | – | FDR: Cholangiocarcinoma | 80+ | localized | ATM | c.2921 + 1G > A | 43.2b | Yes | Gemcitabine | 2 |
| SDR: Glioblastoma | |||||||||||
| 11 | F | breast | FDR: Breast (M), Prostate (P) | 75–80 | localized | BRCA2 | c.1976_1977insSVA | 14.0c | Yes | Gemcitabine | 3 |
| SDR: Breast (M), 4 Prostate (M), Prostate (P) | |||||||||||